Bronşiektazi
Özet
Bronşiektazi, bronş duvarının ve çevre destek dokusunun kronik harabiyeti sonucu havayollarının kalıcı ve anormal şekilde genişlemesiyle karakterize morfolojik bir hastalıktır. Genellikle aylarca süren kronik öksürük, bol mukopürülan balgam çıkarma, nefes darlığı, hemoptizi ve tekrarlayan enfeksiyonlar gibi belirgin klinik bulgularla kendini gösterir. Bilgisayarlı tomografi kullanımının artmasıyla dünya genelinde tanısı hızla artan bu hastalık, özellikle 60 yaş üstü bireylerde ve erkeklere kıyasla kadınlarda daha sık görülmektedir. Patofizyolojisinde Cole tarafından ortaya konulan "kısır döngü" mekanizması hakimdir; bakteriyel enfeksiyonlar inflamasyona ve mukosiliyer temizliğin bozulmasına yol açarak sekresyon birikimine ve daha fazla bronş hasarına neden olur. Silendirik, variköz ve sakküler (kistik) olmak üzere üç klasik tipi bulunan hastalığın tanısında yüksek rezolüsyonlu bilgisayarlı tomografi (YRBT) altın standarttır. Tedavinin temel amacı akut alevlenmeleri azaltmak olup, enfeksiyon kontrolü amacıyla antibiyotikler, solunum fizyoterapisi içeren bronşiyal hijyen teknikleri, mukoaktif ajanlar ve seçilmiş vakalarda cerrahi veya transplantasyon gibi multimodal yöntemler uygulanır. Ayrıca koruyucu hekimlik kapsamında influenza ve pnömokok aşılamaları hayati önem taşır.
Bronchiectasis is a morphological disease characterized by the permanent and abnormal dilation of the airways due to chronic destruction of the bronchial wall and surrounding supportive tissue. It typically presents with distinct clinical signs such as chronic cough lasting for months, copious mucopurulent sputum production, dyspnea, hemoptysis, and recurrent infections. The diagnosis of this disease, which has been rapidly increasing worldwide with the widespread use of computed tomography, exhibits an increased prevalence particularly in individuals over 60 years of age and, unlike COPD, is more common in women. Its pathophysiology is governed by the "vicious vortex" mechanism proposed by Cole, where bacterial infections trigger inflammation and impair mucociliary clearance, leading to secretion retention and further bronchial damage. The disease has three distinct classical types—cylindrical, varicose, and saccular (cystic)—and high-resolution computed tomography (HRCT) is the gold standard for its diagnosis. The primary goal of treatment is to reduce acute exacerbations; thus, multimodal strategies such as antibiotics for infection control, bronchial hygiene techniques including respiratory physiotherapy, mucoactive agents, and in selected cases, surgery or transplantation are utilized. Additionally, influenza and pneumococcal vaccinations carry vital importance within preventive medicine.
Referanslar
Barker A.F., Ahmed S.Y. (2008). Bronchiectasis. In Fishman A.P. (Ed.), Fishman’s Pulmonary Disease and Disorders (Vol 2. 4th ed., pp. 2183-2192). New York: McGrav-Hill.
Iseman M.D., Chan E.D. (2010). Bronchiectasis. In: Mason R.J., Broaddus V.C., Martin T.R., King T.E., Schraufnagel D.E., Murray J.F. & Nadel J.A. (Eds.), Murray & Nadal’s Textbook of Respiratory Medicine (Vol 1. 5th ed., pp. e2424-2481). Philadelphia: Saunders Elsevier.
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50 (3): 1700629.
Barker A.F. (2008). Bronchiectasis. In: Albert R.K., Spiro S.G., Jett J.R. (Eds.), Clinical Respiratory Medicine. (3rd ed., pp. 425-431). Philadelphia: Mosby Elsevier.
Kreit J.W. (2008). Hemoptysis. In: Albert R.K., Spiro S.G., Jett J.R. (Eds.), Clinical Respiratory Medicine. (3rd ed., pp. 311-316). Philadelphia: Mosby Elsevier.
Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018; 392 (10150): 880-890.
O'Donnell AE. Bronchiectasis update. Curr Opin Infect Dis. 2018; 31 (2): 194-198.
Aksamit TR, O'Donnell AE, Barker A, et al. Bronchiectasis Research Registry Consortium. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest. 2017; 151 (5): 982-992.
Rademacher J, Welte T. Bronchiectasis--diagnosis and treatment. Dtsch Arztebl Int. 2011; 108 (48): 809-815.
Bülbül Y, Erçen Diken Ö, Uğur Chousein EG; ASYOD Akciğer İnfeksiyonları ve Tüberküloz Bilim Kurulu. Ulusal yayınlar ışığında Türkiye’de bronşektazi. Tuberk Toraks 2020; 68 (1): 48-65.
Mohammed SK, Jan A. Young Syndrome. 2020 Dec 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Kapania EM, Stern BM, Sharma G. Ciliary Dysfunction. 2021 Oct 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Lewington-Gower E, Chan L, Shah A. Review of current and future therapeutics in ABPA. Ther Adv Chronic Dis. 2021; 12: 20406223211047003.
Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977; 86 (4): 405-414.
Foo CT, Karia S, Herre J. Reversible bronchiectasis. Thorax. 2021:thoraxjnl-2021-217548.
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018; 5 (1): e000348.
National Institute for Health and Care Excellence (NICE) (2018). Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing. NICE guideline [NG117]. (24/01/2022 tarihinde https://www.nice.org.uk/guidance/ng117 adresinden ulaşılmıştır).
O'Neill K, O'Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis. Respirology. 2019; 24 (3): 227-237.
Minov J, Stoleski S, Petrova T, et al. Effects of a Long-Term Use of Carbocysteine on Frequency and Duration of Exacerbations in Patients with Bronchiectasis. Open Access Maced J Med Sci. 2019; 7 (23): 4030-5.
T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Risk grubu aşılamaları. (26/01/2022 tarihinde https://asirehberi.saglik.gov.tr/ uploads/2017-genelgeler/risk/2-risk-grubu-asilamalari-ek-risk-grubu-asilamalari-1-2.html adresinden ulaşılmıştır).
